Royalty Pharma, the world's largest buyer of biopharmaceutical royalties, has established its first Asia-Pacific base in Hong Kong. This move comes as mainland Chinese biotechnology firms are experiencing a surge in out-licensing deals, with the total number of such business development agreements rising 30% year-on-year through May 31, according to an HSBC report released on June 23.
Key Details
The establishment of the Hong Kong office, which opened in May, is part of a broader trend of multinational pharmaceutical companies setting up operations in the city. Kenneth Sun, senior vice-president and head of Asia at Royalty Pharma, noted that royalty financing provides an alternative funding source for drug developers amid increasing U.S. investment restrictions. He stated,
Chinese biotech firms would need royalty financing as an alternative.
Background
The total value of Chinese biotech deals surged 87% during the same period, reflecting a growing interest from global investors in the sector despite geopolitical uncertainties. The shift towards royalty financing is seen as a response to challenges in traditional fundraising channels, particularly in Hong Kong's initial public offering market, which has faced volatility.
Related coverage: Hong Kong IPOs Rise 84% Amid Chinese Tech Surge in 2026.
Sources: scmp.com, forbes.com.
The establishment of Royalty Pharma's office in Hong Kong could enhance the attractiveness of the biotechnology sector, potentially leading to increased investments in biotech stocks and related assets. Investors may closely monitor how this trend impacts funding availability for Chinese biotech firms and overall market sentiment in the sector.
Watch for further developments in Chinese biotech funding and any announcements from Royalty Pharma regarding new partnerships or deals in the region.